Bedfordshire and Luton Joint Formulary Formulary

Searching for : Olaratumab

Open monograph to display formulary status.

Non Formulary items found

Status	Description	Section
DNP	Olaratumab Lartruvo^® (Intravenous infusion)	Malignant disease and immunosuppression, Other antineoplastic drugs, 08.01.05

Links found

MHRA DSU June 2019: Lartruvo¥ (olaratumab): withdrawal of the EU marketing authorisation due to lack of efficacy
NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma